이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Scandion Oncology 대차 대조표 상태

재무 상태 기준 확인 4/6

Scandion Oncology 의 총 주주 지분은 DKK23.6M 이고 총 부채는 DKK0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 DKK26.6M 및 DKK3.1M 입니다.

주요 정보

부채 비율

DKK 0

부채

이자 보상 비율	n/a
현금	DKK 16.96m
주식	DKK 23.55m
총 부채	DKK 3.08m
총 자산	DKK 26.64m

최근 재무 상태 업데이트

We Think Scandion Oncology (STO:SCOL) Needs To Drive Business Growth Carefully

Aug 02

Companies Like Scandion Oncology (STO:SCOL) Are In A Position To Invest In Growth

Feb 01

Here's Why We're Not Too Worried About Scandion Oncology's (STO:SCOL) Cash Burn Situation

May 26

We're Hopeful That Scandion Oncology (NGM:SCOL) Will Use Its Cash Wisely

Jan 06

Recent updates

We Think Scandion Oncology (STO:SCOL) Needs To Drive Business Growth Carefully

Aug 02

Companies Like Scandion Oncology (STO:SCOL) Are In A Position To Invest In Growth

Feb 01

Here's Why We're Not Too Worried About Scandion Oncology's (STO:SCOL) Cash Burn Situation

May 26

We're Hopeful That Scandion Oncology (NGM:SCOL) Will Use Its Cash Wisely

Jan 06

재무 상태 분석

단기부채: SCOL 의 단기 자산 ( DKK23.5M )이 단기 부채( DKK3.1M ).

장기 부채: SCOL 에는 장기 부채가 없습니다.

부채 대 자본 내역 및 분석

부채 수준: SCOL 부채가 없습니다.

부채 감소: SCOL 5년 전에 부채가 없었습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: SCOL 현재 무료 현금 흐름을 기준으로 1년 미만의 cash runway를 보유하고 있습니다.

예측 현금 활주로: 무료 현금 흐름이 매년 32.9 %의 역사적 비율로 계속 감소할 경우 SCOL 의 현금 활주로는 1년 미만입니다.

Scandion Oncology 대차 대조표 상태

재무 상태 기준 확인 4/6

주요 정보

최근 재무 상태 업데이트

We Think Scandion Oncology (STO:SCOL) Needs To Drive Business Growth Carefully

Companies Like Scandion Oncology (STO:SCOL) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Scandion Oncology's (STO:SCOL) Cash Burn Situation

We're Hopeful That Scandion Oncology (NGM:SCOL) Will Use Its Cash Wisely

Recent updates

New major risk - Financial position

Scandion Oncology Reports Second Confirms Partial Response in the Phase IIa CORIST Part 3 Trial

New major risk - Revenue and earnings growth

Scandion Oncology A/S to Report Q3, 2024 Results on Nov 27, 2024

New major risk - Market cap size

Scandion Oncology Reports Positive Topline Phase IIa Data from the CORIST Part 3 Trial

Scandion Oncology A/S, Annual General Meeting, Apr 24, 2024

Scandion Oncology Receives Notice of Allowance for Patent to Enhance US Patent Exclusivity on SCO-101

Price target decreased by 13% to kr2.80

Scandion Oncology Announces Positive Data from Part 2 of its International Multi-Center CORIST Open Label Phase IIa Trial

Scandion Oncology Successfully Completes Phase Ib Pantax Trial Is and Establishes the Maximal Tolerated Dose with Positive Safety Profile and Pharmacokinetic Data

Scandion Oncology A/S Appoints Lars Damstrup, MD, PhD, as Chief Medical Officer

Scandion Oncology A/S Announces Data from PANTAX Trial to Be Presented At ESMO Congress 2023

The European Patent Office Announces Intention to Grant of Composition-Of-Matter Patent for Scandion Oncology's Lead Compound SCO-101

Forecast to breakeven in 2024

Price target decreased by 31% to kr3.40

Forecast to breakeven in 2024

Price target increased by 27% to kr4.95

Scandion Oncology Receives Opinion from the European Patent Office on Composition of Matter Patent-Application for Lead Compound SCO-101

Scandion Oncology Appoints Jan Stenvang, Ph.D., Chief Scientific Officer and Member of Executive Management

Forecast to breakeven in 2024

Scandion Oncology Appoints Francois Martelet as New Chief Executive Officer, Effective from January 2, 2023

Scandion Oncology A/S to Report Fiscal Year 2022 Results on Mar 22, 2023

Consensus revenue estimates fall by 63%

Price target decreased to kr3.90

High number of new and inexperienced directors

Scandion Oncology Initiates Part 3 of CORIST Phase II Trial Studying Scandion’s Lead Compound SCO-101 as Combination Treatment in Patients with Metastatic Colorectal Cancer

Scandion Oncology Announce Topline Results from Part 2 of the Corist Phase II Trial

Scandion Oncology A/S Announces CEO Changes

Scandion Oncology Announces Change to Its Executive Management

Scandion Oncology A/S Receives Approvals for Next Parts of the Corist Trial

Scandion Oncology Extends PANTAX Trial Due to Better-Than-Expected Tolerability of SCO-101

We Think Scandion Oncology (STO:SCOL) Needs To Drive Business Growth Carefully

Consensus forecasts updated

Consensus forecasts updated

Scandion Oncology Announces Resignation of Thomas Feldthus from the Board of Directors

Scandion Oncology A/S Announces Chief Medical Officer Change

Price target increased to kr26.00

High number of new and inexperienced directors

Scandion Oncology A/S Expands Clinical Development with Internationalization of the CORIST-Trial

Companies Like Scandion Oncology (STO:SCOL) Are In A Position To Invest In Growth

Scandion Oncology A/S Announces That Data from CORIST-Trial to Be Presented At ASCO Gastrointestinal Cancers Symposium

Scandion Oncology Receives Approval for Initiating the CORIST Part 2 Trial

Scandion Oncology Receives German Trial Approval for PANTAX Ib Study

Chief Financial Officer Carit Andersen has left the company

Alligator Bioscience AB and Scandion Oncology A/S Present Promising Preclinical Data

Scandion Oncology A/S Reports Positive Interim Results from the Corist Phase II Study

Here's Why We're Not Too Worried About Scandion Oncology's (STO:SCOL) Cash Burn Situation

Scandion Oncology Appoints Dr. Maj Hedtjärn as COO and Head of R&D Operations

Scandion Oncology A/S Adjusts the Pantax Pancreatic Cancer Study

Scandion Oncology A/S Finalizes the First 12 Patients in CORIST Study

We're Hopeful That Scandion Oncology (NGM:SCOL) Will Use Its Cash Wisely

New 90-day low: kr22.20

New 90-day low: kr34.30

New 90-day low: kr35.00

Scandion Oncology A/S Announces Modified Timelines for Clinical Studies

Scandion Oncology A/S Receives Final Approval from the Danish Medicines Agency and Ethical Committee for Start of A Clinical Trial in Patients with Pancreatic Cancer

Scandion Oncology Appoints Bo Rode Hansen as President, Effective October 1, 2020

An unknown buyer acquired 3.96% stake in Scandion Oncology A/S (NGM:SCOL) from Saniona AB (publ) (OM:SANION) for for $2.3 million.

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

현금 런웨이 분석

건강한 기업 발견하기